rs63749869 — RYR1 R4861H (Arg4861His)

The Anesthesia Alarm Hidden in Your Genes

Most people never know they carry a dangerous reaction waiting inside their muscle cells—until the moment a surgeon reaches for a gas mask. Malignant hyperthermia (MH) is a pharmacogenetic crisis of skeletal muscle¹¹ a pharmacogenetic crisis of skeletal muscle
triggered only by specific anesthetic drugs in genetically susceptible individuals. The rs63749869 variant in the RYR1 gene is one of the most well-characterized causes. A carrier who receives a routine volatile anesthetic—sevoflurane, isoflurane, halothane, desflurane—or the muscle relaxant succinylcholine can experience a life-threatening cascade of heat, acid, and rhabdomyolysis within minutes of induction. Before dantrolene became available, the mortality rate exceeded 70%. With prompt treatment it is now under 5%—but only if the anesthesia team knows to act.

The Mechanism

RYR1 encodes the ryanodine receptor 1, the calcium release channel of the skeletal muscle sarcoplasmic reticulum²² calcium release channel of the skeletal muscle sarcoplasmic reticulum
the intracellular calcium store that controls muscle contraction. In a healthy muscle fiber, this channel opens transiently to trigger contraction, then closes. The rs63749869 G>A substitution changes arginine to histidine at position 4861 of the protein (p.Arg4861His), destabilizing the channel's closed state. When a volatile anesthetic molecule binds near this domain, the mutant channel opens uncontrollably and floods the cytoplasm with calcium³³ floods the cytoplasm with calcium
sustained calcium release drives relentless ATP consumption, heat production, and membrane breakdown. The resulting hypermetabolic spiral—rising CO₂, rising temperature, rigidity, acidosis, rhabdomyolysis, hyperkalemia—is fatal without intervention.

Cryo-EM structural mapping of RYR1 shows that pathogenic MHS variants cluster at specific regulatory domains distinct from the pore-forming region implicated in central core disease. The Arg4861 residue lies in this MHS-associated regulatory region, explaining why rs63749869 carriers often show isolated MHS susceptibility without chronic muscle weakness—the channel destabilization is pharmacologically triggered rather than constitutively active.

The Evidence

ClinVar classifies this variant as Pathogenic across multiple submissions (2-star review status, multiple independent submitters including OMIM, Mass General Brigham, and GeneDx), with documented associations to central core myopathy (RCV000013852), general RYR1-related disorder (RCV000119533), and malignant hyperthermia of anesthesia (RCV004017241). In silico predictions are strongly damaging (REVEL: 0.91; 3Cnet: 0.99).

A 2022 expert panel review⁴⁴ 2022 expert panel review
Johnston et al. Human Mol Genet 2022 — classified 251 RYR1 variants using updated VCEP criteria estimated the prevalence of pathogenic RYR1-related MHS at 1 in 300 to 1 in 1,075 individuals—far higher than the 1:5,000–1:50,000 rate of actual MH reactions, because most carriers undergo surgery without triggering exposure or with insufficient volatile agent to cross the crisis threshold.

Snoeck et al. 2015⁵⁵ Snoeck et al. 2015
Dutch multicenter cohort of 77 RYR1-mutation patients across all ages documented the phenotypic spectrum: isolated MH susceptibility, non-anesthesia rhabdomyolysis triggered by vigorous exercise or heat exposure, and congenital myopathy with permanent weakness. The same variant can cause dominant MHS in one family member and recessive myopathy in another—a reminder that penetrance and expressivity vary substantially.

In gnomAD v4 exomes (>400,000 individuals sequenced), this specific allele appears just once across 805,810 chromosomes, confirming its extreme rarity in the general population and its high clinical penetrance when present.

Practical Actions

The most important thing a carrier can do is tell every anesthesiologist before any procedure. Volatile anesthetics (halothane, isoflurane, sevoflurane, desflurane, enflurane) and the depolarizing muscle relaxant succinylcholine must be avoided entirely. Safe alternatives exist: total intravenous anesthesia (TIVA) using propofol, ketamine, opioids, and non-depolarizing muscle relaxants (vecuronium, rocuronium) carries no MH risk for RYR1 carriers. Regional anesthesia (spinal, epidural, nerve blocks) is also safe and preferable when appropriate for the procedure.

Carry a medical alert card or wear a medical alert bracelet identifying yourself as MH-susceptible. The Malignant Hyperthermia Association of the United States (MHAUS)⁶⁶ Malignant Hyperthermia Association of the United States (MHAUS) provides wallet cards and maintains a 24/7 hotline (1-800-644-9737) for anesthesia professionals managing crises.

First-degree relatives (parents, siblings, children) have a 50% chance of carrying the same autosomal dominant variant. Genetic testing of family members—a simple blood draw—can identify who shares the risk before they encounter surgery.

Non-anesthesia triggers are less common but documented: extreme exertion in high ambient heat can precipitate exercise-induced rhabdomyolysis⁷⁷ exercise-induced rhabdomyolysis
muscle breakdown releasing myoglobin, potassium, and creatine kinase into the bloodstream in some RYR1 carriers. If you experience unexpected dark urine, severe muscle pain, or extreme weakness after intense exercise, seek emergency evaluation for rhabdomyolysis.

Interactions

The RYR1 gene harbors hundreds of variants associated with malignant hyperthermia susceptibility and central core disease. rs63749869 (p.Arg4861His) acts through the same channel-destabilization mechanism as other MHS variants in the N-terminal and central regulatory domains. The combined phenotype of compound heterozygosity for two RYR1 variants—one on each chromosome—often produces a more severe recessive myopathy phenotype (congenital weakness, respiratory involvement) rather than isolated MHS. Related variants worth noting include rs118192172 (p.Arg163Cys, a classic MHS hotspot), rs28933400 (p.Gly341Arg), and the many ClinVar-pathogenic MHS alleles catalogued in OMIM entry 180901.